Brevan Howard Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Brevan Howard Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$158K	Sell	14,599 -80,039	-85%	-$913K	﹤0.01%	1940
2026 Q1	$1.05M	Sell	94,638 -182,351	-66%	-$2.3M	0.01%	871
2025 Q4	$4.6M	Buy	276,989 +218,892	+377%	+$3.13M	0.05%	257
2025 Q3	$684K	Buy	58,097 +30,263	+109%	+$312K	﹤0.01%	1117
2025 Q2	$267K	Buy	+27,834	New	+$154K	﹤0.01%	1595
2025 Q1	–	Sell	-22,845	Closed	-$186K	–	1386
2024 Q4	$186K	Buy	+22,845	New	+$283K	﹤0.01%	922
2024 Q3	–	Sell	-18,792	Closed	-$194K	–	1361
2024 Q2	$194K	Buy	+18,792	New	+$194K	﹤0.01%	897

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Brevan Howard Capital Management's PHAT Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Phathom Pharmaceuticals (PHAT) stake by 85% in Q2 2026, selling an estimated $913K and leaving 14,599 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1940.

Brevan Howard Capital Management first reported a position in PHAT in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.6M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Brevan Howard Capital Management held 14,599 shares of Phathom Pharmaceuticals worth $158K as of Q2 2026.
Brevan Howard Capital Management sold 80,039 Phathom Pharmaceuticals shares in Q2 2026, an estimated $913K.
Phathom Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1940 holding.
Brevan Howard Capital Management first reported a position in Phathom Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's Phathom Pharmaceuticals position peaked at $4.6M in Q4 2025.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.